News and Announcements
Prescient Therapeutics Investor Presentation April 2016
- Published April 13, 2016 11:52AM UTC
- Publisher Wholesale Investor
- Categories Company Updates
13th April 2016, ASX Announcement
Investment Summary: Why all the excitement about AML?
- Acute Myeloid Leukemia (AML) is an area of substantial unmet medical need.
– One of the worst survival rates of all cancers
– Standard of care unchanged for 40 years - A disease of intense interest for clinicans, pharma companies and investors
- Celator Pharmaceuticals (NASDAQ: CPXX) showed what can happen when enhancing the standard of care in AML
– Market cap recently surged from small cap to $780M
-Dr Jeff Lancet was the Principal Investigator on CPXX’s ground-breaking trial - PTX has successful Phase 1 trial in AML (conducted at Moffitt and MD Anderson)
To view the full article please click on the button below.
Company Updates
Following the Billions: Where the Hyperscalers are Betting on the Future
The roadmap for the next decade isn’t hidden in pitch decks—it’s written on the balance sheets of Microsoft, Amazon, and Google. Their collective investment is flowing into three key areas: GPU Chips, AI Factories, and Energy. This foundational buildout signals a $7–$20 trillion economic convergence, where the physical race for infrastructure and energy is paramount. The article also covers the powerful macro case for digital assets in this new era.
The Great Re-Allocation: Why AI is Forcing Smart Money From Software to Hard Science
Smart money is rapidly shifting its investment focus from commoditized software to hard science and deep tech, as AI dissolves traditional software moats. Discover the dual pressure on investors and the pivot to businesses with durable, real-world defensive barriers.
AI is The Cheapest, Highest-Leverage Investment You Will Ever Make
AI tools offer a 10x productivity increase for a minimal monthly cost, making them the highest-ROI investment in business today. However, this massive potential remains dormant. The real opportunity is not in owning the tools, but in having the strategic playbook to deploy them organization-wide and build a defensible competitive advantage.
Backed By Leading Investment Groups and Family Offices
